Update on the treatment of patients with non-genotype 1 hepatitis C virus infection

Clinical Infectious Diseases

Volumn 56, Issue 9, 2013, Pages 1294-1300

  Graham, Camilla S ^a   Mangia, Alessandra ^a   Mottola, Leonardo ^a   Piazzolla, Valeria ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

DAA; HCV 2; HCV 3; IFN free; peg IFN; ribavirin

Indexed keywords

DACLATASVIR; INTERLEUKIN 28B; MERICITABINE; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG DOSE REDUCTION; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 84875972667     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1195     Document Type: Article

References (41)

1. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31(suppl 2):30-60.
2. World Health Organization (WHO). Hepatitis C virus. Available at: http://www.who.int/vaccine-reasearch/disease/viral-cancer/en/index2. htlm. Accessed 1 July 2010.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65. (Pubitemid 32913521)
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
5. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120:1438-47. (Pubitemid 32322318)
6. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011; 55:554-63.
7. Piazzolla V, Forte P, Francavilla R, et al. IL28B CC HCV is associated with higher on treatment response rates in pts with HCV-3: interim results of the WRITE study. J Hepatol 2012; 56:S448.
8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62. (Pubitemid 29384163)
9. Petersen J, Lutz T, Link R, et al. Predictive factors for non response in genotype 2/3 infected CHC patients treated with pegIFNα2a and RBV in real-life setting. Program and Abstracts of Digestive Disease Week. San Diego, CA, 2012, Abstract 940.
10. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7. (Pubitemid 28471138)
11. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17. (Pubitemid 41007847)
12. Dalgard O, Bjøro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47:35-42. (Pubitemid 351171039)
13. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56:553-9.
14. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7. (Pubitemid 41096640)
15. Mecenate F, Pellicelli A, Barbaro G, et al. Short versus standard treatment with pegylated interferon alfa2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. BMC Gastroenterology 2010; 10:21.
16. Shiffman ML, Suter F, Bacon BR, et al. ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124-34. (Pubitemid 47057730)
17. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008; 47:1837-45. (Pubitemid 351945551)
18. Diago M, Shiffman ML, Bronowicki JP, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KDa) plus ribavirin. Hepatology 2010; 51:1897-903.
19. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
20. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
21. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011; 54: 789-800.
22. Mangia A, Minerva N, Bacca D, et al. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 2009; 49:358-63.
23. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51:388-97.
24. Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141:881-9.e1.
25. Fried MW, Hadziyannis S, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55:69-75.
26. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 and 3 who do not achieve a rapid virologic response. Gastroenterology 2010; 139:821-7.e1.
27. Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54:415-21.
28. Lindh M, Lagging M, Farkkila M, et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis 2011; 203:1748-52.
29. Scherzer TM, Hofer H, Staettermayer AF, et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54:866-71.
30. Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53:746-54.
31. Bochud PY, Cai T, Overbeck K, et al.; Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis. J Hepatol 2009; 51:655-66.
32. Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology 2012; 142:1288-92.
33. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37:837-42. (Pubitemid 35404224)
34. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130:1636-42.
35. Mangia A, Bandiera F, Montalto G, et al. Individualized treatment with combination of peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol 2010; 53:1000-5.
36. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136:1618-28.
37. Gane EJ, Stedman CA, Hyland RH, et al. ELECTRON: once daily PSI-7977 plus ribavirin in HCV GT1/2/3. J Hepatol 2012; 56:(suppl 2) S438-9.
38. Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/-ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3. J Hepatol 2012; 56(suppl 2): S560.
39. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54:1250-62.
40. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment naïve genotype 4 HCV patients. J Hepatol 2009; 50(suppl 1):S6.
41. Pawlotsky JM, Najera I, Jacobson I. Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 2012; 17:411-23.